Vergleich der Auswirkungen von Smart-App-unterstütztem Super-Langsam-Jogging und stationärem Radfahren auf die Atemfunktion und aerobe Fitness bei College-Studenten
As health awareness continues to rise, more people are prioritizing exercise to improve physical condition and enhance overall fitness. For those lacking exercise habits, selecting a simple, accessible, and effective workout becomes crucial. Against a backdrop of prolonged sitting and inactivity, "super slow jogging" is gaining attention. This aerobic exercise involves a slow walking pace and low intensity, yet burns more calories than regular walking, making it an ideal entry-level activity for beginners or those with lower fitness levels. This study aims to investigate whether incorporating super slow jogging training can effectively enhance cardiorespiratory fitness and respiratory function, comparing its outcomes with other exercise types. The purpose of this experiment is academic research, primarily exploring the impact of exercise intervention on physiological functions. It is not intended for health screening or medical diagnosis.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Daliao
-
Kaohsiung City, Daliao, Taiwan, 831301
- No. 151, Jinxue Rd.
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- required no regular exercise training in the past six months
- ability to safely perform high-intensity cycling exercise
Exclusion Criteria:
- musculoskeletal limitations that prevented cycling exercise
- recent infection
- known cardiopulmonary disease or medical history affecting cardiovascular or respiratory function
- smoking
- use of medications that may influence cardiopulmonary responses to exercise
- other contraindications to exercise testing according to the American College of Sports Medicine (ACSM) guidelines
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Super slow jogging
A smart app will provide pacing assistance, adjusting step frequency weekly: Week 1: 150 steps per minute Week 2: 180 steps per minute Week 3: 190 steps per minute Week 4: 200 steps per minute |
This study is a randomized controlled trial employing simple randomization, where participants draw lots to assign groups. The experiment comprises three groups: the super-slow jogging group, the stationary bicycle group, and the control group. Both exercise intervention groups underwent 50-minute training sessions comprising a 10-minute warm-up, 30-minute main exercise, and 10-minute cool-down. Super-Slow Jogging Group: Utilized a smart app for pacing assistance, adjusting step frequency weekly: Week 1: 150 steps/minute Week 2: 180 steps/minute Week 3: 190 steps/minute Week 4: 200 steps/minute Stationary Cycling Group: Participants will engage in continuous cycling training at moderate intensity (60% VO₂max). Control Group: No exercise training intervention. |
|
Experimental: moderate exercise training
Continuous cycling training at moderate intensity of 60% VO₂max |
This study is a randomized controlled trial employing simple randomization, where participants draw lots to assign groups. The experiment comprises three groups: the super-slow jogging group, the stationary bicycle group, and the control group. Both exercise intervention groups underwent 50-minute training sessions comprising a 10-minute warm-up, 30-minute main exercise, and 10-minute cool-down. Super-Slow Jogging Group: Utilized a smart app for pacing assistance, adjusting step frequency weekly: Week 1: 150 steps/minute Week 2: 180 steps/minute Week 3: 190 steps/minute Week 4: 200 steps/minute Stationary Cycling Group: Participants will engage in continuous cycling training at moderate intensity (60% VO₂max). Control Group: No exercise training intervention. |
|
Placebo-Komparator: Control
not perform any exercise training |
This study is a randomized controlled trial employing simple randomization, where participants draw lots to assign groups. The experiment comprises three groups: the super-slow jogging group, the stationary bicycle group, and the control group. Both exercise intervention groups underwent 50-minute training sessions comprising a 10-minute warm-up, 30-minute main exercise, and 10-minute cool-down. Super-Slow Jogging Group: Utilized a smart app for pacing assistance, adjusting step frequency weekly: Week 1: 150 steps/minute Week 2: 180 steps/minute Week 3: 190 steps/minute Week 4: 200 steps/minute Stationary Cycling Group: Participants will engage in continuous cycling training at moderate intensity (60% VO₂max). Control Group: No exercise training intervention. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Cardiopulmonary Fitness
Zeitfenster: Before intervention and the end of intervention at 12 weeks
|
VO2max (ml/kg/mL) |
Before intervention and the end of intervention at 12 weeks
|
|
Baseline anthropometric of the participants
Zeitfenster: Before intervention and the end of intervention at 12 weeks
|
Age (yr) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Zeitfenster: Before intervention and the end of intervention at 12 weeks
|
VEmax (L/min) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Zeitfenster: Before intervention and the end of intervention at 12 weeks
|
AT% (%VO₂max) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Zeitfenster: Before intervention and the end of intervention at 12 weeks
|
Resting O₂ pulse (mL·beat-¹) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Zeitfenster: Before intervention and the end of intervention at 12 weeks
|
Max O₂ pulse (mL·beat-¹) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Zeitfenster: Before intervention and the end of intervention at 12 weeks
|
MIP (cmH2O) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Zeitfenster: Before intervention and the end of intervention at 12 weeks
|
MEP (cmH2O) |
Before intervention and the end of intervention at 12 weeks
|
|
Baseline anthropometric of the participants
Zeitfenster: Before intervention and the end of intervention at 12 weeks
|
Height (cm) |
Before intervention and the end of intervention at 12 weeks
|
|
Baseline anthropometric of the participants
Zeitfenster: Before intervention and the end of intervention at 12 weeks
|
Weight (kg) |
Before intervention and the end of intervention at 12 weeks
|
|
Baseline anthropometric of the participants
Zeitfenster: Before intervention and the end of intervention at 12 weeks
|
BMI (kg/m²) |
Before intervention and the end of intervention at 12 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Lung function
Zeitfenster: Before intervention and the end of intervention at 12 weeks
|
FEV1 (L) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Zeitfenster: Before intervention and the end of intervention at 12 weeks
|
FVC (L) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Zeitfenster: Before intervention and the end of intervention at 12 weeks
|
FEV₁/FVC (%) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Zeitfenster: Before intervention and the end of intervention at 12 weeks
|
FEF25-75% (L·s-¹) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Zeitfenster: Before intervention and the end of intervention at 12 weeks
|
PEF (L·min-¹) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Zeitfenster: Before intervention and the end of intervention at 12 weeks
|
MVV (L·min-¹) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Zeitfenster: Before intervention and the end of intervention at 12 weeks
|
Breathing reserve (%) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Zeitfenster: Before intervention and the end of intervention at 12 weeks
|
Dynamic Index (DI%) |
Before intervention and the end of intervention at 12 weeks
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- 114-0561
- 114-2813-C-242-003-B (Andere Zuschuss-/Finanzierungsnummer: National Science and Technology Council, Taiwan)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .